It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

These include Alzheimer's disease treatment Kisunla, eczema therapy Ebglyss, and ulcerative colitis drug Omvoh. These medicines aren't yet contributing to Eli Lilly's already impressive top-line ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

Jaypirca and Omvoh should also contribute meaningfully through the end of the decade. In other words, Eli Lilly's revenue should continue growing at a good clip. The midpoint of the company's ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two ...